The first poster presentation revealed that treating acute myeloid leukemia (AML) cells with imetelstat enhanced the effects of agents currently used for treating the disease.
The second showed results from non-clinical studies, which backed up findings of previous clinical trials, concerning blood platelet production.
The work was presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting held in New Orleans, Louisiana.
Imetelstat inhibits the activity of telomerase - an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely.
Imetelstat has not, as yet, been approved for marketing by any regulatory authority.
The firm is developing the treatment under a collaboration agreement with Janssen Biotech, Inc.
In late 2014, Geron entered an exclusive worldwide license and collaboration agreement with Janssen to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses.
Under the terms, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales.
Certain regulatory, development, manufacturing and promotional activities are being managed through a joint governance structure, with Janssen responsible for these activities.
Janssen is conducting two imetelstat clinical trials: a Phase 2 clinical trial in patients with intermediate-2 and high risk myelofibrosis (MF) and a Phase 2/3 clinical trial in patients with low and intermediate-1 risk myelodysplastic syndromes (MDS).